Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Controlled, Multicenter, Open Label Study With Blinded Assessment of the Efficacy of the Humanized Anti-IL 23p19 Risankizumab Compared to FUMADERM in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy

Trial Profile

A Randomized, Controlled, Multicenter, Open Label Study With Blinded Assessment of the Efficacy of the Humanized Anti-IL 23p19 Risankizumab Compared to FUMADERM in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2018

At a glance

  • Drugs Risankizumab (Primary) ; Calcium monoethyl fumarate/dimethyl fumarate/magnesium monoethyl fumarate/zinc monoethyl fumarate; Dimethyl fumarate
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 13 Jul 2018 Status changed from active, no longer recruiting to completed.
    • 26 Apr 2018 Planned End Date changed from 27 Jun 2018 to 15 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top